[HTML][HTML] The evolution of drug resistance in clinical isolates of Candida albicans
Candida albicans is both a member of the healthy human microbiome and a major pathogen
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
[HTML][HTML] The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci… - eLife, 2015 - ncbi.nlm.nih.gov
Candida albicans is both a member of the healthy human microbiome and a major pathogen
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
[PDF][PDF] The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci… - 2015 - Citeseer
Candida albicans is both a member of the healthy human microbiome and a major pathogen
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
[PDF][PDF] The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci… - digital.wpi.edu
Candida albicans is both a member of the healthy human microbiome and a major pathogen
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
[PDF][PDF] The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci… - core.ac.uk
Candida albicans is both a member of the healthy human microbiome and a major pathogen
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci… - 2015 - agris.fao.org
Candida albicans is both a member of the healthy human microbiome and a major pathogen
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci… - eLife, 2015 - cir.nii.ac.jp
抄録< jats: p> Candida albicans is both a member of the healthy human microbiome and a
major pathogen in immunocompromised individuals. Infections are typically treated with …
major pathogen in immunocompromised individuals. Infections are typically treated with …
The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci… - …, 2015 - pubmed.ncbi.nlm.nih.gov
Candida albicans is both a member of the healthy human microbiome and a major pathogen
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
[PDF][PDF] The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci… - scienceopen.com
Candida albicans is both a member of the healthy human microbiome and a major pathogen
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
in immunocompromised individuals. Infections are typically treated with azole inhibitors of …
The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci… - eLife, 2015 - sonar.ch
English Candida albicans is both a member of the healthy human microbiome and a major
pathogen in immunocompromised individuals. Infections are typically treated with azole …
pathogen in immunocompromised individuals. Infections are typically treated with azole …